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Improved Antitumor Response to Isolated Limb Perfusion With 
Tumor Necrosis Factor After Upregulation of Endothelial 
Monocyte-Activating Polypeptide II in Soft Tissue Sarcoma 
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Background: Experiments with tumor necrosis factor a (TNF) in rodents have shown that a high 
dose can lead to hemorrhagic necrosis in tumors. Endothelial monocyte-activating polypeptide II 
(EMAP-II) is a novel tumor-derived cytokine, and its expression i creases the TNF-1 receptor on 
tumor endothelium, enhances the induction of tissue factor on tumor endothelial cells, and has an 
antiangiogenic effect. It has recently been shown that in vivo sensitivity of tumor vasculature toTNF 
is determined by tumor production of EMAP-II. 
Methods: We measured the level of EMAP-II in a TNF-resistant soft tissue sarcoma. We 
subsequently stabile-transfected thiscell line with a retroviral construct containing the EMAP gene. 
In an extremity perfusion model in tumor-beating rats, we measured response rates to TNF therapy. 
Results: Functional EMAP-II production was increased after this transfection. Immunostaining of 
paraffin-embedded tumor tissue sections in rats showed an overexpression f human EMAP-II. 
Results of the TNF perfusions in rats suggest that this tumor is more sensitive to TNF therapy. 
Conclusions: EMAP-II is produced in various levels. One can increase the sensitivity of tumor 
for TNF therapy in vivo by upregulating the EMAP-II production. This result leaves an opportunity 
for enhanced TNF response of tumors in future settings. 
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Studies of the antitumor activity of systemically admin- 
istered tumor necrosis factor (TNF) in humans have been 
hampered by severe dose-limiting toxicity at relatively low 
doses of the cytokine which are insufficient for an antitumor 
response.1 This situation changed when TNF was applied in 
the isolated limb perfusion (ILP) setting. The efficacy of the 
application of TNF in combination with cytostatic agents in 
ILP for the treatment of patients with in-transit melanoma 
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metastases or locally advanced soft tissue sarcomas has 
now been well established, l~ This treatment can be used as 
a limb-sparing neoadjuvant therapy when it is followed by 
local excision of residual tumor. TNF became a registered 
cancer drug in Europe on the basis of results obtained in 
multicenter studies in which clinical response rates of 75% 
and limb salvage rates of 71% were observed in 196 pa- 
tients who had been classified as having unresectable tu- 
mors that could have been managed only by amputation. 
Approval by the European Agency for the Evaluation of 
Medicinal Products was given for the use of TNF in the 
setting of an ILP for locally advanced extremity grade II to 
I l l  soft tissue sarcomas. 4 However, 25% of all patients 
remain in whom we cannot achieve a sufficient antitumor 
effect for limb preservation. The answer as to why this 
group of patients is not responding is not known. 
There is evidence that the mechanism of action of TNF 
is not directly on tumor cells, but that it acts indirectly by 
destruction of tumor-associated endothelium. 5 This destruc- 
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tion may eventually lead to the death of tumor cells when 
TNF is used in combination with an antitumor drug. The 
antitumor effects after TNF-containing ILPs can be ex- 
tremely rapid, indicating that the TNF-mediated collapse of 
the tumor vascular bed may play an essential role in the 
antitumor mechanism. The selective destructive effects of 
TNF ILP on tumor-associated vessels have been illustrated 
in the clinic by means of pre- and postperfusion angiogra- 
phy.~ Severe hemorrhagic necrosis accompanied with vas- 
cular destruction was observed after ILP with TNF in 
combination with melphalan. 
Our laboratory has developed ILP models with different 
tumors in rats to study prerequisites for improving efficacy 
and to study mechanisms of synergy. 6,7 These models 
mimic the clinical setting closely with respect to response 
rate and histopathology. The crucial observation has been 
that TNF selectively and highly significantly enhances the 
uptake of melphalan and doxorubicin in the tumors. 6 
Endothelial monocyte-activating polypeptide II (EMAP- 
II) is a tumor-derived cytokine with proinflammatory prop- 
erties. It induces procoagulant activity on the surface of 
endothelial cells and monocytes/macrophages in vitro, as 
well as upregulation ofE- and P-selectin expression and the 
ability to upregulate TNF receptor-1 expression on tumor 
vasculature. Furthermore, EMAP-II induces apoptosis and 
has antiangiogenic effects. 1 These data led us to hypothe- 
size that EMAP-II could be of additional benefit in the TNF 
perfusion circuit. Wu et al.8 defined a way to upregulate 
EMAP-II production by means of retroviral transfection i
a melanoma cell line. We used this method of transfection 
on a TNF-resistant soft tissue sarcoma. We describe here 
the application of the sensitizing ene therapy and subse- 
quent regional TNF treatment and its effects on in vivo 
tumor growth. Because EMAP-II can have additional ben- 
efits in long-term anticancer t eatment regarding its antian- 
giogenic effect (e.g., to prevent outgrowth of neovascula- 
ture and metastases) and is toxic when injected 
systemically, a long-lasting and local production of 
EMAP-II in a tumor should be favorable. This can be 
maintained after retroviral transfection and subsequent up- 
regulation of the protein synthesis by tumor cells. It was our 
goal to identify factors of TNF resistance or sensitivity and 
the potential role of EMAP-II in this. 
MATERIALS AND METHODS 
Animals 
Inbred male Brown Norway (BN) rats, weighing 200 to 
300 g, were obtained from Harlan-CPB (Austerlitz, The 
Netherlands). All animals were kept at standard laboratory 
conditions and were fed a standard laboratory diet (Hope 
Farms, Woerden, The Netherlands). The experimental pro- 
tocols adhered to the rules laid down in the Dutch Animal 
Experimentation Act (1977) and the published Guidelines 
on the Protection of Experimental Animals by the council of 
the European Community (1986). All animal studies were 
performed in accordance with protocols approved by the 
Animal Care Committee of the Erasmus University of Rot- 
terdam, The Netherlands. 
Tumor Cell Lines 
BN-175 is a nonimmunogenic, rapidly growing soft 
tissue sarcoma syngeneic in BN rats, with a tumor 
doubling time of approximately 2 to 3 days. This 
tumor was implanted into the flank of donor rats and 
passaged serially. For this study we used small tumor 
fragments (+1 mm 2) that were subcutaneously im- 
planted into the right hind limb just above the ankle. 
All surgical interventions were performed at a tumor 
diameter of 5 to 10 mm, at least 7 days after implan- 
tation. Rats were killed if tumor diameter exceeded 25 
mm. The human umbilical vein endothelial cells 
(HUVECs) used were obtained from BioWhittaker 
Europe (Verviers, Belgium) and consisted of pooled 
cells by multiple donors. 
Drugs 
Recombinant human TNF-ce (4.9-5.8 • 107 U/mg), 
recombinant human EMAP-II (hEMAP-II; 3.85 ~g/mL), 
and antibodies directed to hEMAP-II were provided as a 
kind gift by Dr. G. Adolf (Boehringer Ingelheim GmbH, 
Vienna, Germany). 
Transfection of BN-175 Tumor Cells With the 
EMAP.H Gene 
Viral supematant from the Gibbon Ape ecotropic 
packaging cell line PG-WU was used to transfect he 
BN-175 tumor cell line. Tumors were grown in six-well 
plates to approximately 40% confluence. The viral su- 
pernatant was then collected and filtered across a .45-~Lm 
low-protein-binding membrane (Coming Costar, Cam- 
bridge, MA), and polybrene (Sequa Brene; Sigma, St. 
Louis, MO) was added at a concentration of 1 /xl/mL of 
supematant. Tumor cells were washed twice with phos- 
phate-buffered saline (PBS) and incubated for 6 hours on 
3 subsequent days in an incubator at 37~ and 5% CO 2. 
In between incubation with viral supernatant, cells were 
given normal medium to recover. After 5 to 7 days, the 
transfected tumor cells (named BN-E) were placed into 
75-cm 2flasks and expanded under neomycin selection at 
800/xg/mL. 
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Detection of Incorporation of hEMAP in Genomic 
DNA of Rat Tumor Cells by PCR 
Transfected tumor cells growing in 800 /xg/mL of 
neomycin were trypsinated and pelleted. DNA was ex- 
tracted with the QIamp DNA minikit (Qiagen Inc., Va- 
lencia, CA) and amplified by PCR by using primers 
specific for both a part of the EMAP insert and the 
downstream retroviral internal ribosome entry site re- 
gion. For EMAP, the following primers were used: 5'- 
AATCGGATGGTGATTTTACTTTGTA-3' at both 
times as the forward primer and backward; 5'-CATTT- 
TATTTGATTCCACTGTTGC-3' with a PCR product of 
333 base pairs (bp) for the EMAP part; and backward for 
the internal ribosome entry site and EMAP 5'-GAAT- 
GCTCGTCAAGAAGACAG-3', providing a 577-bp 
PCR product. PCR amplification was performed under 
the following conditions: 5 minutes at 95~ 35 cycles 
(94~ for 45 seconds, 55~ for 45 seconds, and 72~ for 
60 seconds); and 7 minutes at 72~ soak at 4~ Am- 
plified PCR products were subjected to gel electrophore- 
sis on a 1% agarose gel containing ethidium bromide. 
Western Blot Analysis of Transfected Tumor Cells 
for EMAP 
After transfection of the tumor cells, cells were col- 
lected, washed, and centrifuged. Cell pellets were lysed 
at 4~ in a buffer containing 50 mM TrisC1 (pH 8.0), 150 
mM NaC1, .02% Na-azide, .1% sodium dodecyl sulfate, 
1 /xg/mL of aprotinin, 5% Na-deoxycholate, 1% Nonidet 
P-40 (Sigma-Aldrich, Zwijndrecht, The Netherlands), 
deoxyribonuclease I 10 ng/mL, and 100/xg/mL of phe- 
nylmethyl sulfonyl fluoride for 10 minutes. Samples 
were vortexed, and debris was pelleted by centrifugation 
at 15,000 X g for 10 minutes. Supernatant protein con- 
tent was determined by BCA protein assay (Pierce 
Chemical Co., Rockford, IL), and a final loading con- 
centration of 120/xg per sample was used. Lysates were 
mixed with Laemmli buffer containing 5%/3-mercapto- 
ethanol, boiled for 5 minutes, and electrophoresed on a 
15% acrylamide gel by using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis. The membranes 
were subsequently blocked for nonspecific binding over- 
night at 4~ with PBS/5% nonfat dry milk/.05% Tween 
and incubated for 2 hours with EMAP-II polyclonal 
rabbit antiserum (diluted 1/2000 in PBS/5% nonfat dry 
milk/.05% Tween). After washing thoroughly, the mem- 
branes were incubated for 1 hour with biotinylated goat 
anti-rabbit mmunoglobulin G antiserum (diluted 1/3000 
in PBS/5% nonfat dry milk/.05% Tween). Membranes 
were again washed and incubated with alkaline phos- 
phatase-labeled streptavidin and developed with en- 
hanced chemiluminescence by adding bromo-cloro- 
indolyl-phosphate/nitro-blue-tetrazolium. 
Coagulation Assay 
Conditioned medium from wild-type BN-175 and 
BN-E tumor cell lines was tested for procoagulant activ- 
ity by using a two-stage coagulation assay. HUVECs 
were grown to -80% confluence in six-well multiwell 
tissue culture plates in complete ndothelial growth me- 
dia (Cambrex Bio Science, Baltimore, MD). Cells were 
washed twice with sterile PBS. Tumor-conditioned me- 
dium was produced by growing -5 X 106 tumor cells per 
75-cm 2 tissue culture flask in 15 mL of serum-free me- 
dium. After 24 hours, conditioned medium was collected 
and vacuum-filtered across a .45-/xm membrane to re- 
move cellular debris and was used directly. HUVECs 
were treated at a concentration of 1 mL of conditioned 
medium per well. Normal medium was used as a nega- 
tive control, and TNF-c~ at a concentration of 1 /xglmL of 
medium was used as a positive control. The samples 
were incubated for 6 hours at 37~ in a 5% CO 2 incu- 
bator and assayed for procoagulant activity. Medium was 
removed from the treated HUVECs, and cells were 
washed with Ca/Mg-free PBS. After l0 minutes of in- 
cubation with 1 mL of 25 mM Tris/ethylenediaminetet- 
raacetic acid (pH 7.4) per well, cells could be gently 
removed from the wells and subsequently collected and 
centrifuged at 14,000 • g for 10 minutes at room tem- 
perature. Supernatant was carefully removed, and the 
resultant cell pellet was resuspended in a 100-/xl assay 
buffer (buffer: 250/xl of 1 M Tris; 300/3,1 of 5 M NaCI; 
10 mg of. 1% bovine serum albumin; distilled H2 O to 10 
mL) and shortly vortexed. Cell pellet was added to 100 
/xl of human citrated plasma (Biopool, Venture, CA), 
mixed well, and incubated at 37~ for 3 minutes in a 
clinical fibrometer. The coagulation reaction was cata- 
lyzed by adding 100 /xl of 30 mM CaC12 (Sigma), and 
clotting time was measured. Standard curves were gen- 
erated by using lipidated recombinant human tissue fac- 
tor (American Diagnostica, Greenwich, CT). 
Immunohistochemical Staining of hEMAP in Rat 
Tumor Tissue 
Tumor was induced by subcutaneous injection of -2 X 
106 BN or BN-E tumor cells in the flank region of 
syngeneic BN rats. When the tumor reached 10 mm in 
diameter, it was resected from the animal, immediately 
fixated in 4% formalin, and embedded in paraffin. As- 
sessment of tumor morphology was performed on 5- to 
8-/xm hematoxylin and eosin-stained sections. Before 
staining for EMAP-II, sections were dewaxed with xy- 
lene and rehydrated by passing through a graded series of 
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alcohol (100%-70%) followed by PBS. Sections were 
microwaved two times for 5 minutes in .01 M citrate 
buffer (2.10 g/L of citric acid and 1 g/L of sodium 
hydroxide) to enhance immunoreactivity. All incubations 
were performed in a humidified chamber at room tem- 
perature. Sections were incubated in 5% normal goat 
serum for 30 minutes to block nonspecific binding of 
antibodies. Sections were rinsed with PBSFFween, and 
rabbit polyclonal antibody against hEMAP-II was added 
at a 1/100 dilution. Polyclonal rabbit immunoglobulin G 
(Santa Cruz Biotechnology, Santa Cruz, CA) was used as 
a negative control. Sections were incubated for 1 hour, 
washed three times with PBS, and subsequently incu- 
bated with goat anti-rabbit secondary antibody conju- 
gated to peroxidase for 1 hour. After washing three times 
in PBS, slides were incubated with the avidin-biotin 
complex reagent, followed by diaminobenzidine sub- 
strate. Thereafter the slides were rinsed with distilled 
water and counterstained with hematoxylin. Finally, 
slides were dehydrated with graded alcohol and xylene 
and covered with DPX. Sections were examined with a 
Leica (Wetzlar, Germany) DM-RXA microscope, and 
images were made by using a Sony (Tokyo, Japan) 
DXC950 digital camera. 
ILP Model 
The perfusion technique was performed as described 
previously. 6,7,9 In our laboratory, Manusama et al. 7 mod- 
ified the technique of ILP in rats, originally described by 
Benckhuijsen et al. 1~ In this model, by using the BN-175 
soft tissue sarcoma, it was shown that only when TNF 
was combined with melphalan or doxorubicin could a 
tumor esponse be reached. In comparison to the clinical 
setting, our rat model demonstrated partial or complete 
regression of the tumor in approximately 75% of rats 
receiving an ILP with melphalan plus TNF. We used the 
BN-175 soft tissue sarcoma to set up an experimental 
environment where we could improve the response rate 
to TNF. 
Briefly, small fragments (3-5 mm) of tumor were 
implanted subcutaneously into the right hind limb of the 
rat. Approximately 7 to 8 days after implantation, tumors 
reached an average diameter of 8 to 12 mm, and then 
treatment was started. Animals were anesthetized with 
Hypnorm (Janssen Pharmaceutica, Tilburg, The Nether- 
lands) and ketamine (Apharmo BV, Arnhem, The Neth- 
erlands). Heparin (50 IU) was injected intravenously to 
prevent coagulation. To keep the rat's hind limb at a 
constant emperature, a warm-water mattress was ap- 
plied. Temperature was measured with a temperature 
probe on the skin covering the tumor and was maintained 
between 38~ and 39~ The femoral artery and vein 
were cannulated with silastic tubing (.012-inch inner 
diameter, .025-inch outer diameter; and .025-inch inner 
diameter, .047 inch outer diameter, respectively; Dow 
Coming, Midland, MI). Collaterals were occluded by a 
groin tourniquet, and the time of isolation started when 
the tourniquet was tightened. An oxygenation reservoir 
and a roller pump were included into the circuit. The 
perfusion solution consisted of 5 mL of Hemaccel (Be- 
hring Pharma, Amsterdam, The Netherlands) in the sham 
perfusions, and TNF (50/zg) was added to the oxygen- 
ation reservoir as a bolus in the treatment group. A roller 
pump (type 505 U; Watson Marlow, Falmouth, UK) 
recirculated the perfusate at a flow rate of 2.4 mL/min. A 
washout with 5 mL of oxygenated Hemaccel was per- 
formed at the end of the perfusion. After the perfusion, 
the cannulas were removed, and the femoral vessels of 
the perfused limb were ligated. The extensive collateral 
circulation was capable of restoring the blood supply of 
the perfused leg. 
The perfusion with the wild-type tumor took place 16 
hours after intravenous injection with recombinant 
EMAP-II. In these experiments, 50 /xg of recombinant 
EMAP-II, dissolved in 200 /xl of PBS, was injected 
intravenously. Rats were closely monitored afterward, 
and moderate but reversible toxicity was observed after 
IV administration. Subsequent tumor growth was re- 
corded daily by caliper measurement. Tumor volume 
was calculated as .4 X (A 2 X B), where B represents he 
longest diameter and A the diameter perpendicular to B. 
RESULTS 
Transfection of the EMAP.H Gene 
Rat soft tissue sarcoma cells were transfected in vitro 
with retroviral particles containing the P. Wu construct 
(BN-E) and seemed resistant o continuous exposure 
with 800 /zg/mL of neomycin, demonstrating effective 
transfection with the construct (data not shown). After 2 
weeks of growing in selection media, genomic DNA was 
extracted from the transfected tumor cell lines. PCR 
analysis of expression of the EMAP-II gene proved pos- 
itive for the BN-E cell line (data not shown). Western 
blot analysis of 120 p,g of protein of cell lysate of 
wild-type and transfected tumor cells, compared with 
100 ng of recombinant EMAP-II, demonstrated a band 
corresponding tothe size of the human precursor EMAP- 
II, -34 kDa (Fig. 1). We show only the results with 
normally growing tumor cells. In our ongoing experi- 
ments, we would like to demonstrate he generation of 
active EMAP-II (-22 kDa) that was used as a control in 
these experiments, and we would like to show interme- 
diate cleavage products by inducing apoptosis in the 
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FIG. 1. Western blots were performed 
with t20 /zg of protein isolated from cell 
lysate from transfected cell lines. PS, pro- 
tein scale; C, control recombinant human 
endothelial monocyte-activating polypep- 
tide II (100 ng); BN, wild-type tumor; 
BN-E, transfected tumor. 
tumor cells. However, this expression seems to be very 
unstable and transient and shows tremendous variation. 
Coagulation Assay 
We wanted to test whether the EMAP-II-transfected 
cell line, BN-E, produced functional protein. We used a 
functional bioassay of EMAP-II activity based on the 
induction of tissue factor expression on human endothe- 
lial cells. HUVECs were treated with conditioned me- 
dium of transfected tumor cells. As shown in Fig. 2, a 
6-hour exposure of HUVECs to medium conditioned by 
tumor transfected with EMAP-II (BN-E) induced a 20% 
increase in the production of tissue factor by these cells, 
as compared with treatment with conditioned medium 
from wild-type BN or medium alone. 
Immunohistochemical Staining of hEMAP in Rat 
Tumor Tissue 
The tumor model used for our in vivo studies was gen- 
erated by subcutaneous injection of 2 • 10 6 transfected 
tumor cells in the hind limb of a syngeneic BN rat. Tumors 
were grown to an average diameter of 8-12 ram, and we 
observed a growth rate corresponding to a wild-type tumor. 
As shown in Fig. 3, cells stained positive for EMAP-II as 
compared with controls. On the hematoxylin and eosin 
staining (Fig. 4), the morphology of the transfected tumor 
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FIG. 2. Tissue factor assay. Lane 1: Positive control; medium of cells 
treated with 1 p~g of tumor necrosis factor c~. Lane 2: Medium of 
untreated cells. Lane 3: Wild-type tumor medium (BN). Lane 4: 
Transfected tumor medium (BN-E). Conc TF, concentration f recom- 
binant human tissue factor (American Diagnostica, Greenwich, CT). 
was altered with a tendency to more apoptotic cells. This, 
however, was not reflected in the growth rate of the BN-E. 
We regard this as apoptosis being induced by the increased 
EMAP-II production of this tumor. 
ILP in Rats With Transfected Tumor 
In Figure 5, the results of TNF ILP in rats bearing the 
BN-E tumor compared with the wild-type tumor are 
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FIG. 3. Immunohistochemical staining with human endothelial 
monocyte-activating polypeptide II (hEMAP-II) (• 100). (A) Nontrans- 
fected tumor. (B) Marked upregulation of the intracellular present 
hEMAP-1I. 
shown. Perfusion with Hemaccel alone resulted in pro- 
gressive disease in all animals. Although ILP with TNF 
resulted in a slight inhibition of tumor growth of the 
wild-type BN tumor compared with the sham control, 
there was no significant difference in tumor esponse. As 
can be seen in this graph, the EMAP-II-transfected tu- 
mor BN-E responded significantly better to ILP with 50 
/xg of TNF. We saw macroscopically a more profound 
necrosis in the BN-E tumor that led to a significantly 
slower outgrowth of tumor after the perfusion. Even in 
animals with transfected tumors, a small rim of viable 
tumor cells survived. However, as can be seen at day 9, 
the overall observed response rate still implied a decline 
in tumor dimension, whereas profound recurrent tumor 
growth was demonstrated in all animals from day 11. 
FIG. 4. Hematoxylin and eosin stained tumor sections (• (A) 
Normal morphology of wild-type viable tumor cells. (B) Transfected 
tumor is shown with an aspect of more profound ecrosis, disruption of 
cell structure, and smaller cells. 
ILP in Rats Preceded by Recombinant EMAP-II 
Injection 
A total of 50 /xg of recombinant EMAP-II was in- 
jected intravenously into rats 16 hours before TNF per- 
fusion. Rats showed a moderate toxic response immedi- 
ately after injection; nevertheless, this was reversible 
within 4 hours. Figure 6 shows the tumor volume of 
animals treated with TNF perfusion after pretreatment 
with recombinant EMAP-II. Sham perfusions after 
EMAP-II injection were also performed. From the sec- 
ond day, a significant difference in tumor volume was 
observed in TNF-treated animals bearing the BN-E ver- 
sus wild-type tumor. Tumors treated with sham perfusion 
or TNF ILP alone continued to grow; the recombinant 
EMAP-II pretreated animals showed a delay in tumor 
growth after TNF ILP. This difference was observed 
until the ninth day, when both groups started to develop 
the same growth rate. Both wild-type and BN-E tumors 
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FIG. 5. Growth curves of wild-type tumor after isolated limb perfu- 
sion (ILP) with sham ([5]) (n = 5) and tumor necrosis factor (TNF) (A) 
(n = 7) and of transfected tumor after ILP with sham (T) (n = 7) and 
TNF (~) (n = 5). 
showed the same growth rate in the presence of system- 
ically administered recombinant EMAP-II alone. 
DISCUSSION 
The results presented in this study show that transfec- 
tion with EMAP-II of the TNF-resistant tumor BN-175 
will render this tumor TNF sensitive and responsive to 
ILP treatment with TNF. This approach could enhance 
efficacy in the clinical setting, where 25% of patients 
with locally advanced limb-threatening extremity soft 
tissue sarcoma do not respond to TNF plus chemother- 
apy in the ILP setting for limb salvage to be achieved. 
By introducing isolated perfusion as a mode to apply 
TNF in patients, we have been able to achieve effective 
concentrations of TNF in the tumor region. Antitumor ef- 
fects after TNF-containing ILPs can be extremely rapid. 
This indicates that also in humans the TNF-mediated col- 
lapse of the tumor vascular bed plays an essential role in the 
antitumor mechanism, as has been illustrated in publica- 
tions on clinical studies by pre- and postperfusion angiog- 
raphy. L~ Moreover, in studies in sarcoma patients with 
magnetic resonance spectrometry, we have clearly shown 
that the metabolic shutdown of the tumor is virtually com- 
plete within 16 hours after the perfusion, confn'ming the 
likelihood of TNF mediating its most import,ant effects on 
the vasculature of the tumor, n At the histopathologic level, 
these intravascular effects--such as thrombocyte aggrega- 
tion, erythrostasis, and endothelial and vascular destruc- 
t ion-have been described for the early-stage changes after 
ILP, which may closely resemble observations made in 
experimental tumor systems.l 1 
Because TNF is known to act on the tumor endothe- 
lium, a range of cytotoxic agents have been used in 
combination to have an additional antitumor effect. After 
8000- 
~ 6000- 
9 ~ 4000- 
2000- 
o I 
o 14 
Days 
FIG. 6. Results of isolated limb perfusion (ILP) in wild-type (BN) 
tumor. Control tumor ([]), n = 6; sham perfusion, (C,) n = 5; tumor 
necrosis factor (TNF) (A), n = 7; endothelial monocyte-activating 
polypeptide II (EMAP-II) followed by sham perfusion (o); and ILP 
with EMAP-II plus TNF (IB), n = 6. 
the initial destruction of tumor vessels, these agents can 
exert their toxic effect on the tumor cells. 
We introduce here an approach based on a different 
mechanism toimprove the effect of TNF therapy. After the 
observation that varying tumors respond in a distinct man- 
ner to TNF, a cytokine that contributes to this response was 
isolated. This cytokine, EMAP-II, is produced by tumors 
and influences the formation of neovasculature in a number 
of ways, one of them being the upregulation of TNF recep- 
tor-1 on tumor-associated endothelial cells. This is an im- 
portant finding regarding the use of TNF as anticancer 
therapy. 
Therefore, we investigated whether we could enhance 
the TNF sensitivity of a nonresponding rat sarcoma in 
vivo by transfecting the tumor with EMAP-II, to increase 
its endogenous EMAP-II content. EMAP-II is a tumor- 
derived cytokine with proinflammatory properties, in- 
ducing procoagulant activity on the surface of endothe- 
lial cells and monocytes/macrophages in vitro, as well as 
upregulation of E- and P-selectin expression and the 
ability to upregulate TNF receptor-1 expression on tumor 
vasculature. ]2 The distribution of EMAP-II protein is 
relatively restricted and is usually associated with tissues 
that display high turnover and high levels of protein 
synthesis, e.g., tumor t issue. 13 It was first isolated from 
the conditioned medium of the murine methylchol- 
antrene A-induced fibrosarcoma. This tumor responds 
well to TNF therapy, and investigators found that in the 
supernatant of this tumor, the cytokine EMAP-II was 
excreted. Studies have shown that EMAP-II is capable of 
sensitizing resistant umors to the antitumor effects of 
TNF. 14:5 In response to EMAP-II exposure, endothelial 
cells are activated, and the expression of TNF receptor- 1 
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is upregulated, an effect that is known to take place 
between 16 and 24 hours after exposure to EMAP-II.~5 It 
led us to hypothesize that EMAP-II could be of addi- 
tional benefit in the TNF perfusion circuit, This enabled 
us to create a more sensitive tumor to TNF therapy, 
without the toxic side effects of systemic EMAP-II ap- 
plication. In our next experiments, we injected recombi- 
nant hEMAP into rats that were 16 hours later subjected 
to an ILP system with TNF. With a dose of 50 /xg of 
recombinant EMAP per rat combined with 50 /xg of 
TNF, we saw a significant decrease of growth of the 
tumors, with an immediate, although moderate and re- 
versible, toxic reaction to the injected EMAP-II. These 
results were comparable with the effect seen in the trans- 
fected tumor and suggest that this effect is mediated by 
EMAP-II, rather than being an effect created by trans- 
fection of the tumor or an effect seen because of varying 
levels of EMAP-II receptors. 
ILP is an interesting method for new treatment modali- 
ties, such as adenoviral vector-mediated gene therapy. 16,17 
In oar laboratory, we have shown that ILP is the best and 
most selective method for effective homogeneous transvas- 
cular local gene delivery by using adenoviral vectors. Ex- 
periments in our soft tissue sarcoma nd osteosarcoma ILP 
models have clearly shown this by making use of lucif- 
erase-marker gene and LacZ gene methodology/8 More- 
over, we have shown that ILP with adenoviral vector gene 
delivery of the cytokine interleukin-3 is the only method in 
these tumor models to achieve good tumor responses, in 
contrast to the failure of other methods, such as intravenous 
administration, intra-arterial dministration, or intratumoral 
administration. 17 It demonstrates that ILP is a valuable 
method to treat advanced limb tumors and to develop new 
treatment modalities. 
The possibility of manipulating the sensitivity for TNF 
in a tumor in vivo also leaves a window for systemic 
application of TNF in future settings. If noninvasive 
vectors can increase tumor sensitivity in a way that the 
TNF dose can be decreased, we might be able to save 
patients in the future by the invasive perfusion procedure 
and be able to administer TNF systemically. 
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